Dr. Timothy M. Block is President and Co-founder of the Hepatitis B Foundation; its research arm, the Baruch S. Blumberg Institute; and the Pennsylvania Biotechnology Center. His work, with Baruch S.Blumberg, Anand Mehta and Raymond Dwek, pioneered the use of glycoproteomics for detection of biomarkers of liver cancer, leading to the use of Golph2/GP73 and core fucosylated serum proteins as risk stratifiers for liver cirrhosis and hepatocellular carcinoma. His work with Ying Su led to use of “microDNA” detected in the urine as a cancer marker. More recently, he and his colleagues (Ju-Tao Guo, Hai-Tao Guo, Andy Cuconati) have identified small molecule inhibitors of hepatitis B virus,and was the initial technology in creation of the company, Oncore (now called Arbutus).
Dr. Block has received numerous honors, including election to the US National Academy of Inventors (2017), Hon. Medical Doctors Degree from the Bulgarian National Academy, Fellow, American Association for the Advancement of Science and Fellow, Glycobiology The University of Oxford. With his wife, Joan, he is co-recipient of the American Association for Liver Diseases’ first Distinguished Public Service Advocacy Award (2021). He is scientific co-founder of several life sciences companies, co-inventor on 20 issued patents and 23 applications, has co-authored more than 270 scholarly papers, and was named a “Visionary in Hepatitis” by the World Hepatitis Alliance in 2017. He is also Adjunct Professor at Geisinger Commonwealth School of Medicine and the University of Pennsylvania School of Medicine.